Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen kYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%) (%)
Form 8-K Product Sales Performance & Form 10-Q / 10-K MD&A
Latest, Q3 2023
8.0%
Period ended Sep 30, 2023
Change on a year earlier
-3.0 pts
11.0% in Q3 2022
History
7 quarters
Since Q3 2021
Sources
7
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2023 | Sep 30, 2023 | 8.0% | -3.0 pts | Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗ |
| Q2 2023 | Jun 30, 2023 | 15.0% | -4.0 pts | Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗ |
| Q1 2023 | Mar 31, 2023 | 18.0% | +5.0 pts | Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗ |
| Q3 2022 | Sep 30, 2022 | 11.0% | +1.0 pts | Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗ |
| Q2 2022 | Jun 30, 2022 | 19.0% | – | Form 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 13.0% | – | Form 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗ |
| Q3 2021 | Sep 30, 2021 | 10.0% | – | Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗ |
Cite this data
StockData. (2026). Amgen KYPROLIS (carfilzomib — Relapsed/Refractory Multiple Myeloma) — Worldwide volume growth YoY (%) (%), quarterly Q3 2021–Q3 2023 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_kyprolis_vol
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.